Latest / StartUp Health NOW Podcast
Breaking News: Sinaptica’s Noninvasive Neuromodulation Device Slows Alzheimer’s Disease in Year-Long Trial
Hear the latest groundbreaking news in Alzheimer’s research. Sinaptica, a member of StartUp Health’s Alzheimer’s Moonshot Community, has announced significant results from its Phase 2 clinical trial testing the company’s noninvasive, personalized, precise neuromodulation designed to stop the progression of Alzheimer’s disease.
Ken Mariash, CEO of Sinaptica, joined us in the StartUp Health Studio to break it all down for us. As you’ll hear, the interview took place prior to the release of this data, which became public on October 31.
In this exclusive interview, you’ll learn:
Details on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.